Upper Respiratory Tract Infections Clinical Trial
Official title:
Effectiveness of the NoseFrida Compared With Bulb Suction at Relieving Objective Signs of Nasal Obstruction and Reducing Return Visits in Pediatric Patients Presenting to the Emergency Department
The mainstay of treatment in viral upper and lower respiratory tract disease is airway clearance. Viral respiratory tract infections account for a substantial amount of emergency department (ED) visits, financial and stress burden on caregivers. In addition, they also account for a large number of ED return visits. While airway clearance is considered a mainstay of treatment the pragmatic effectiveness of various devices remain unstudied in patients who are discharged from the ED. The objectives of this study are to compare the pragmatic effectiveness of two commonly used suction devices the NoseFrida and bulb suction and to provide a descriptive analysis on 72 hour return to ED rates and readmission rates. Patients will be enrolled October 15, 2018 to October 15, 2019 or until NoseFrida supplies are depleted. Fridababy will supply 500 NoseFrida devices and replacement filters. Patients aged 1 day to 24 months presenting Vanderbilt Childrens ED with symptoms of nasal congestion or bronchiolitis who require suctioning and will be discharged from the ED will be approached for enrollment. Exclusion criteria include no upper airway abnormalities or previously enrolled in study. The study design is a prospective and retrospective observational study. We anticipate about 500 patients to be enrolled in this study. Families will then be approached for consent to participate. Caregiver will fill out a data collection form then be instructed on how to use the NoseFrida. Next, family with trial it on their child while in the ED. Caregivers will then fill out a 7 point Likert survey on both the bulb suction and NoseFrida device. The family will go home with this device and a set of replacement filters and instructed to suction their child as needed. The primary investigator (PI) will then complete a 72 hour chart review to determine the number of return to ED visits and readmission rates. To compare ED returns with retrospective data, KSP will conduct a review of the business objects database using ICD9 codes specific for viral respiratory tract infections over the past 3 years to determine a control return ED visit rate. Data will be compared using a paired T-test. If data is not normally distributed we will use a Wilcoxon signed-rank test. We will also use a multivariable logistic model to examine associations adjusted for age and illness severity.
Background The mainstay of treatment in viral upper and lower respiratory tract disease is airway clearance. Viral respiratory tract infections account for a substantial amount of emergency department (ED) visits, financial and stress burden on caregivers. In addition, they also account for a large number of ED return visits. While airway clearance is considered a mainstay of treatment the pragmatic effectiveness of various devices remain unstudied in patients who are discharged from the ED. Hypothesis: There is no difference between the NoseFrida and the bulb suction at relieving objective signs of nasal obstruction or return ED visits. Study Objective: 1. To compare the use of the NoseFrida device with a retrospective control (bulb suction) to determine if there is a decrease in the number of ED return visits. 2. To provide evidence based recommendations on the pragmatic effectiveness of two commonly used suction devices. 3. To provide a descriptive analysis on 72 hour return to ED rates and readmission rates. Methods: The study design is a prospective and retrospective observational study. We anticipate about 500 patients to be enrolled in this study. Patients who present to Vanderbilt Childrens Emergency Department will be identified by key study personnel (KSP) based on inclusion and exclusion criteria. Families will then be approached for consent to participate. Caregiver will fill out a data collection form then be instructed on how to use the NoseFrida. Next, family with trial it on their child while in the ED. Caregivers will then fill out a 7 point Likert survey on both the bulb suction and NoseFrida device. The family will go home with this device and a set of replacement filters and instructed to suction their child as needed. The primary investigator (PI) will then complete a 72 hour chart review to determine the number of return to ED visits and readmission rates. The family will keep the suction device at the completion of the study. To compare ED returns with retrospective data, KSP will conduct a review of the business objects database using ICD9 codes specific for viral respiratory tract infections over the past 3 years to determine a control return ED visit rate. Data will be compared using a paired T-test. If data is not normally distributed we will use a Wilcoxon signed-rank test. We will also use a multivariable logistic model to examine associations adjusted for age and illness severity. Fridababy will provide supplies needed for the study, however the company will not have access to the raw data or PHI. Once the results are published in a scientific journal, then Fridababy will have access to the results. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT00965822 -
A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
|
Phase 2 | |
Completed |
NCT01019889 -
Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection
|
Phase 3 | |
Not yet recruiting |
NCT05484102 -
Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children
|
N/A | |
Recruiting |
NCT05804123 -
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
|
N/A | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01773824 -
Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care
|
N/A | |
Completed |
NCT01883427 -
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
|
Phase 2 | |
Completed |
NCT01215682 -
Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers
|
N/A | |
Completed |
NCT04019730 -
The Effect of a Ketogenic Diet on the Exercise Induced Immune Response
|
N/A | |
Completed |
NCT01604096 -
Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy
|
Phase 2 | |
Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
Recruiting |
NCT03463694 -
Edinburgh and Lothian Virus Intervention Study in Kids
|
N/A | |
Completed |
NCT06127186 -
Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
|
||
Completed |
NCT03198676 -
A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production
|
Phase 1 | |
Withdrawn |
NCT05557214 -
Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers
|
N/A | |
Completed |
NCT01893762 -
Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes
|
N/A | |
Completed |
NCT01129128 -
Three Arm Trial of Immune Effects of Echinacea
|
N/A | |
Completed |
NCT01396889 -
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
|
N/A | |
Completed |
NCT05252468 -
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
|
N/A |